ALLA DANILKOVITCH – Osiris Therapeutics, Inc.
Alla Danilkovitch, Ph.D.,
Chief Scientific Officer of Osiris Therapeutics, Inc.

Alla Danilkovitch joined Osiris in 2003. At Osiris Dr. Danilkovitch is responsible for development of Osiris’ product pipeline and lead Research and Development, Medical Affairs and Clinical Operations.She is a researcher with more than 25 years of experience in Academia, US Government and Industry combined. She has a proven record of successful product development from scientific ideas to market launch, which includes the world’s first approved mesenchymal stem cell drug, remestemcel-L (Prochymal™), for graft-versus-host disease, as well as BIO4™ for bone repair, Cartiform® for cartilage repair, Grafix® for acute and chronic wounds, and Stravix™ for soft tissue repair. Her areas of scientific expertise include cellular and molecular biology and immunology, cell biochemistry and signal transduction, assay development and validation, stem cell biology and cellular regenerative medicine product development. She is an active member of several professional societies and a current reviewer for many peer-reviewed journals including Stem Cells, Allergy & Inflammation, Advances in Wound Care and others. Dr. Danilkovitch has an extensive list of awards (13), publications (50) and patent applications (55). She also has extensive mentoring experience with deep understanding of the importance of teaching a new generation of scientists. Prior to joining Osiris, Dr. Danilkovitch conducted research at the National Cancer Institute of National Institutes of Health, the Max Planck Institute of Biochemistry in Munich, Germany, the EtvosLorand University, Budapest, Hungary, and at Moscow State University, Moscow, Russia. She earned a Ph.D. in Cell Biology and a M.S. in Cellular Immunology and Microbiology from Moscow State University. She also has a RN degree in Pediatrics from Moscow Regional School of Nursing, Russia.

Advancement in Cell and Tissue Preservation for Commercial Success

Cell therapy is a key part of regenerative medicine that provides solutions to many conditions that otherwise cannot be addressed by medical devices, pharmaceuticals, and biological drugs. Despite the high potential and over 200 years of experience with cell therapies, the number of available cellular treatments and their beneficial impact on patients are limited. Many applications are still emerging and remain in the experimental stages. The challenges of developing a robust manufacturing process and the complex logistics for storage and distribution of cellular therapies play a significant role in delaying cell therapy progress. This lecture overviews advances in cell and tissue preservation methods with a focus on the novel lyopreservation technology allowing ambient storage of cellular therapies. This eliminates the need for ultralow temperature storage and distribution, a limiting factor in the use of cellular therapies. It is expected that the novel technology will accelerate development, commercialization, and widespread use of cellular therapies.